DEVELOPMENT OF NETWORK OF CANCER FAMILY SYNDROME REGISTRIES IN EASTERN EUROPE Project co-ordinator: Prof. Jan Lubiński Hereditary Cancer Centre, Pomeranian.

Slides:



Advertisements
Similar presentations
EuroPa - Establishment of an European Network of Excellence Müller, M.(1), Neumann, H.(2), Jungraithmeier, T., Almann, F. J., Wagner, M., Smith, S. (1)
Advertisements

FROM EUROCHIP-1 TO EUROCHIP-2 EUROCHIP-2 - The action Public Health Program EUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL.
Breast MR Imaging Workshop th September 2014 High-Risk Screening Evidence-based Clinical Indications for Breast MRI Dr. Muhamad Zabidi Ahmad, AMDI.
Gene 210 Cancer Genomics April 29, Key events in investigating the cancer genome M R Stratton Science 2011;331:
Lynch Syndrome and Colorectal Cancer Steven G. Proshan, M.D. Annapolis Colon and Rectal Surgeons Anne Arundel Medical Center November 8,
THE EUROCHIP PROJECTS Health Indicators for Health Indicators for Monitoring Cancer in Europe
Integrating Genomics into Clinical Practice Jan Dorman, PhD University of Pittsburgh School of Nursing
EUROCHIP - EUROpean Cancer Health Indicators Project A fight against disequalities in managing cancer HMP HMP: Health Monitoring Programme Andrea Micheli.
The management of outpatients with stable coronary artery disease in clinical practice.
A few thoughts on cancer and cancer family syndromes Pamela McGrann, MD. Department of Medical Genetics.
COLORECTAL BLEEDING: a multidisciplinary approach Torino, 31 marzo-1 aprile 2006 GENETIC EVALUATION Schena M, Angelini F, Bertetto O. Department of Medical.
Hereditary Factors in Breast Cancer
The Genetics of Breast and Ovarian Cancer Susceptibility Patricia Tonin, PhD Associate Professor Depts. Medicine, Human Genetics & Oncology McGill University.
Lecture 22 Cancer Genetics II: Inherited Susceptibility to Cancer Stephen B. Gruber, MD, PhD November 19, 2002.
Genetics and Ovarian Cancer Jeanne M. Schilder, M.D. Associate Professor, Gynecologic Oncology Indiana University Medical Center September 19, 2012.
Hereditary ovarian/breast cancers (HOC/HBOC) Chair and Department of Surgical Gynecology and Gynecological Oncology of Adults and Adolescents. Head: Prof.
Hereditary Breast & Ovarian Cancer Syndrome HBOC Tammy McKamie RN MSN OCN Cancer Genetics Educator Clinical Oncology Patient Navigator.
Estimating the penetrances of breast and ovarian cancer in the carriers of BRCA1/2 mutations Silvano Presciuttini University of Pisa, Italy.
Cancer Genetics Diane Stirling McMillan Nurse Specialist in Genetics
Morning Report May 20, 2009 Bridger Clarke  Born in Lawrence, Massachusetts, on 4 January  Dropped out of high school at the age of fourteen.
1 Development of Hereditary Cancer Prevention Measures in Pskov Region Asoc. Prof. Edvīns Miklaševičs, Riga Stradins University 16 November 2011, St.Petersburg,
Gene 210 Cancer Genomics May 5, Key events in investigating the cancer genome M R Stratton Science 2011;331:
Cancer Genetics for Primary Care Sara Levene Registered Genetic Counsellor.
Breast Cancer Research in the Developing World Dr. Steven Narod Canada Research Chair in Breast Cancer Boston – November 2009.
Cancer Genetics. Issues Colorectal guidelines – Awaiting publication of coloproctologists guidance – SIGN / QIS update started Breast / ovarian – Breast.
EUROCHIP - EUROpean Cancer Health Indicators Project A project supported by the European Commission Andrea Micheli 1, Paolo Baili 1, Carmen Martinez 2,
Breast Screening. NHS Breast Screening Programme Introduced in 1988 Invites women from age group for screening every 3 yrs. Age extension roll-out.
Immunohistochemistry (IHC) for Microsatellite Instability Fact Sheet Frequently Asked Questions What is Lynch Syndrome? Lynch syndrome is a hereditary.
FORCE XRAY PROGRAM Evaluating Reports on Breast Cancer in the Media.
The Cancer Pedigree BRCA What?. Outline Introduction: Understanding the weight of genetics in Ovarian Breast Cancer BRCA 1 and BRCA 2 Genes – Function.
© Dr Whitcomb Familial Pancreatic Cancer Families (and other high-risk people) David C Whitcomb MD PhD Giant Eagle Foundation Professor of Cancer Genetics.
Genetics and Ovarian Cancer June 16, 2015 Ovarian Cancer Alliance of Oregon and SW Washington Becky Clark, MS, CGC Genetic Counselor.
1 EUROPA DONNA – The European Breast Cancer Coalition Susan Knox, Executive Director KEEPING BREAST CANCER ON THE EUROPEAN HEALTH AGENDA.
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
COST 356 EST - Towards the definition of a measurable environmentally sustainable transport CONTACTS Dr Robert Joumard, chairman, INRETS, tel
Sexual health in Europe Dr Keith Radcliffe European Regional Director International Union against Sexually Transmitted Infections (IUSTI)
NOT ALL PAST SUCCESSES IN CANCER RESEARCH HAVE BEEN FOLLOWED BY ACTIONS EUROCHIP-2 THE ACTION Project & news EUROCHIP-2 THE ACTION Project & news Public.
Prof. Janusz Limon, MD, PhD
Angelina Jolie The White Coat Wonder. Rational  The purpose of our research is to enrich the Premed-A community with the knowledge of other cancers caused.
World Wide Prostate cancer coalition Moving forward together : The solution T. Hudson Geneva,
Statistics about unknown primary tumors Riccardo Capocaccia National Centre for Epidemiology, Surveillance and Health Promotion Istituto Superiore di Sanità,
BOadicea Antonis Antoniou Cancer Research - UK
A An Eastern Partnership Conference An Eastern Partnership Conference 5-6 th December 2011, Kiev 5-6 th December 2011, Kiev.
1945  Second World War ended  Europe united as the European Coal and Steel Community, the founding members of this organisation were Belgium, France,
Chester Ellesmere Port & Neston Rural Making sure you get the healthcare you need West Cheshire CCG Strategy Dr Andy McAlavey Medical Director West Cheshire.
Breast Ovarian Hereditary Breast & Ovarian Cancer Knowing one’s family medical history can be life-saving.
HTA Benefits and Risks Dr Bernard Merkel European Commission.
Uterine Cancer Endometrial (or uterine) cancer will account for 50,000 new cases and 8200 deaths in the United States in Two genetic disorders are.
Genetic predisposition to
Introduction Hereditary predisposition (mutations in BRCA1 and BRCA2 genes) contribute to familial breast cancers. Eighty percent of the.
2010 HIV/AIDS surveillance in Europe European Centre for Disease Prevention and Control, Stockholm WHO Regional Office for Europe, Copenhagen.
Pancreatic Cancer In 2012 there were 43,920 cases of pancreatic cancer. 10% of these cases have a family clustering of pancreatic cancers and associated.
Breast Cancer Ten percent of breast cancer is hereditary. Or 23,000 women a year with a genetic basis for their cancer. The most common mutations in this.
Do you have 3 or more affected relatives? (2 or less)
Cancer Genetic Counseling and Familial Cancer Risk Assessment Program Zohra Ali-Khan Catts, MS LCGC Helen F. Graham Cancer Center Christiana Care Health.
Genetic Counseling Yahwardiah Siregar Sry Suryani W Mutiara Indah Sari.
The National Cancer Research Network is part of the National Institute for Health Research CANCER GENETIC TRIALS Leicestershire, Northamptonshire and Rutland.
Hereditary Cancer Predisposition: Updates in Genetic Testing
European-Comparative Effectiveness Research on online Depression Treatment E-COMPARED is funded by the European Community’s Seventh Framework.
Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.
Hereditary Gastrointestinal Cancers
Lorraine Hartles West Midlands Regional Genetics Laboratory
Counseling Patients About Germline BRCA Mutations
Results Questionnaire
EU: First- & Second-Generation Immigrants
When Should We Suspect Hereditary Colorectal Cancer Syndrome?
Genetic Counseling & Testing for Cancer Risk
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined.
Specific Tumor Suppressor Genes
HBOC Genetic counseling: major concerns and communication skills
Presentation transcript:

DEVELOPMENT OF NETWORK OF CANCER FAMILY SYNDROME REGISTRIES IN EASTERN EUROPE Project co-ordinator: Prof. Jan Lubiński Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland

NETWORK OF CANCER FAMILY SYNDROME REGISTERS IN EASTERN EUROPE EU PROJECT

PROJECT PARTICIPANTS:  Prof. P. Boesze (Hungary),  Dr. P. Elsakov (Lithuania),  Dr. L. Foretova (Czech Republic),  Prof. J. Gardovskis (Latvia),  Prof. N. Haites (United Kingdom),  Dr. G. Moeslein (Germany),  Prof. H. Neumann (Germany),  Prof. B. Ponder (United Kingdom),  Prof. H. Sobol (France),  Dr. H. Vasen (Netherlands),  Dr. W. Weber (Switzerland),  J.-P. Mecklin (Finnland – subcontractor)  Prof. P. Boesze (Hungary),  Dr. P. Elsakov (Lithuania),  Dr. L. Foretova (Czech Republic),  Prof. J. Gardovskis (Latvia),  Prof. N. Haites (United Kingdom),  Dr. G. Moeslein (Germany),  Prof. H. Neumann (Germany),  Prof. B. Ponder (United Kingdom),  Prof. H. Sobol (France),  Dr. H. Vasen (Netherlands),  Dr. W. Weber (Switzerland),  J.-P. Mecklin (Finnland – subcontractor)

THE SCIENTIFIC OBJECTIVES OF THE PROJECT INCLUDED: 1.Elaboration of standards for a model cancer family syndrome (CFS) registries in Eastern Europe 2.Registration of 2000 families with different types of CFS in populations of East European countries (Czech Republic, Hungary, Latvia, Lithuania, Poland) 3.Initiation of European collaborative studies with the use of material collected by East European CFS registries 1.Elaboration of standards for a model cancer family syndrome (CFS) registries in Eastern Europe 2.Registration of 2000 families with different types of CFS in populations of East European countries (Czech Republic, Hungary, Latvia, Lithuania, Poland) 3.Initiation of European collaborative studies with the use of material collected by East European CFS registries

RESULTS: Ad 1. In the initial phase of the project, East European scientists visited Western centres in United Kingdom, Germany, France and Netherlands and performed analyses of existing situation in their countries. On the basis of these and literature data, all of the project participants formulated diagnosis and conclusions concerning development of the model CFS registry in Eastern Europe and described standards of a model organisational structure of Hereditary Cancer Centres in Eastern Europe. Ad 1. In the initial phase of the project, East European scientists visited Western centres in United Kingdom, Germany, France and Netherlands and performed analyses of existing situation in their countries. On the basis of these and literature data, all of the project participants formulated diagnosis and conclusions concerning development of the model CFS registry in Eastern Europe and described standards of a model organisational structure of Hereditary Cancer Centres in Eastern Europe.

RESULTS:

PARTICULAR ACHIEVEMENTS  Registration of ~1300 BRCA 1 mutation carriers  1,253 mln of 1,45 mln of inhabitants in West – Pomerania, Poland screened for CFS  Registration of ~1300 BRCA 1 mutation carriers  1,253 mln of 1,45 mln of inhabitants in West – Pomerania, Poland screened for CFS

TWÓJ STYL

RESULTS: Ad 3. Collaborative studies: A. Ongoing: 1.Clinical characteristics of families with FH gene constitutional mutations – Cybulski C., Mecklin J.P., Lubinski J. 2.Classification of hereditary cancers based on changes at protein level – Europroteome – Berlin – Lubinski J. 3.Modifying genes in patients with BRCA 1 constitutional mutations – Hamman U., Goldgar D., Scott R.J., Gronwald J., Lubinski J. 4.Nature and frequency of MSH 6 gene mutations in Latvia – Irmejs A., Gardovskis J., Kurzawski G., Suchy J., Lubinski J. 5.Family ascertainment and sample collection for identification of additional breast cancer susceptibility genes in the BRCAX study – Lubinski J., Goldgar D. 6.Average risk of breast and ovarian cancer associated with mutations in BRCA1 and BRCA2 detected in case series unselected for family history - Pharoah P., Ponder B., Narod S., Gronwald J., Lubinski J. Ad 3. Collaborative studies: A. Ongoing: 1.Clinical characteristics of families with FH gene constitutional mutations – Cybulski C., Mecklin J.P., Lubinski J. 2.Classification of hereditary cancers based on changes at protein level – Europroteome – Berlin – Lubinski J. 3.Modifying genes in patients with BRCA 1 constitutional mutations – Hamman U., Goldgar D., Scott R.J., Gronwald J., Lubinski J. 4.Nature and frequency of MSH 6 gene mutations in Latvia – Irmejs A., Gardovskis J., Kurzawski G., Suchy J., Lubinski J. 5.Family ascertainment and sample collection for identification of additional breast cancer susceptibility genes in the BRCAX study – Lubinski J., Goldgar D. 6.Average risk of breast and ovarian cancer associated with mutations in BRCA1 and BRCA2 detected in case series unselected for family history - Pharoah P., Ponder B., Narod S., Gronwald J., Lubinski J.

RESULTS: Ad 3. Collaborative studies: A. Ongoing: 7.Nuclear pedigree criteria of suspected HNPCC – Kladny J., Moeslein G., Lubinski J. 8.Founder mutations in the BRCA 1 gene in west Belarusian breast-ovarian cancer families – Oszurek O., Lubinski J. 9.Germline MSH 2 and MLH 1 mutational spectrum in HNPCC families from Poland and Baltic states – Kurzawski G., Elsakov P., Gardovskis J., Irmejs A., Moeslein G., Lubinski J. 10.Concerted Action Polyp Prevention 2. A randomised controlled trial of colorectal polyp and cancer prevention using aspirin in carriers of HNPCC – Lubinski J., Elsakov P., Burn J. 11.Stem Cell Therapeutics – Excellence Centre - Dembinska-Kiec A., Lubinski J. 12.Centre of Excellence in Molecular Bio-Medicine – Witt M., Lubinski J. 13.Excellence Centre for Hereditary Cancers (Network of Excellence) – Lubinski J., Elsakov P., Foretova L., Gardovskis J., Haites N., Ponder B., Moeslein G., Neumann H., Sobol H., Mecklin J.-P., Vasen H., Weber W. Ad 3. Collaborative studies: A. Ongoing: 7.Nuclear pedigree criteria of suspected HNPCC – Kladny J., Moeslein G., Lubinski J. 8.Founder mutations in the BRCA 1 gene in west Belarusian breast-ovarian cancer families – Oszurek O., Lubinski J. 9.Germline MSH 2 and MLH 1 mutational spectrum in HNPCC families from Poland and Baltic states – Kurzawski G., Elsakov P., Gardovskis J., Irmejs A., Moeslein G., Lubinski J. 10.Concerted Action Polyp Prevention 2. A randomised controlled trial of colorectal polyp and cancer prevention using aspirin in carriers of HNPCC – Lubinski J., Elsakov P., Burn J. 11.Stem Cell Therapeutics – Excellence Centre - Dembinska-Kiec A., Lubinski J. 12.Centre of Excellence in Molecular Bio-Medicine – Witt M., Lubinski J. 13.Excellence Centre for Hereditary Cancers (Network of Excellence) – Lubinski J., Elsakov P., Foretova L., Gardovskis J., Haites N., Ponder B., Moeslein G., Neumann H., Sobol H., Mecklin J.-P., Vasen H., Weber W.

RESULTS: Ad 3. Collaborative studies: B. Proposed: 1.Letters of Expression of Interest for 6th Framework Programme (European Commission): -Identification of Men with a genetic predisposition to prostate cancer and their treatment – Eeles R. -Assessment of the therapeutic response in breast cancer - Sobol H. -Clinical management of familial breast cancer (Network of Excellence) – Eccles D. -Prevention of hereditary endometrial cancer – Vasen H. -Colorectal cancer genetics: insight into cause and prevention (Network of Excellence) - Burn J. -Public health systems in combating hereditary cancers (Network of Excellence) – Lubinski J. Ad 3. Collaborative studies: B. Proposed: 1.Letters of Expression of Interest for 6th Framework Programme (European Commission): -Identification of Men with a genetic predisposition to prostate cancer and their treatment – Eeles R. -Assessment of the therapeutic response in breast cancer - Sobol H. -Clinical management of familial breast cancer (Network of Excellence) – Eccles D. -Prevention of hereditary endometrial cancer – Vasen H. -Colorectal cancer genetics: insight into cause and prevention (Network of Excellence) - Burn J. -Public health systems in combating hereditary cancers (Network of Excellence) – Lubinski J.

RESULTS: Ad 3. Collaborative studies: B. Proposed: 2.Modifying genes in patients with mutations within HNPCC genes – Scott R.J., Irmejs A., Kurzawski G., Marlicz K., Lubinski J. 3.Incidence of BRCA 2 constitutional mutations in families with aggregation of stomach and ovarian cancers – Jakubowska A., Starzynska T., Lubinski J., Caldas C. 4.Clinical characteristics of familial pancreatic cancers – Nej K., Starzynska T., Marlicz K., Lubinski J., Moeslein G. Ad 3. Collaborative studies: B. Proposed: 2.Modifying genes in patients with mutations within HNPCC genes – Scott R.J., Irmejs A., Kurzawski G., Marlicz K., Lubinski J. 3.Incidence of BRCA 2 constitutional mutations in families with aggregation of stomach and ovarian cancers – Jakubowska A., Starzynska T., Lubinski J., Caldas C. 4.Clinical characteristics of familial pancreatic cancers – Nej K., Starzynska T., Marlicz K., Lubinski J., Moeslein G.

WELCOME TO DEVELOP COLLABORATIVE STUDIES WITH PARTICIPATION OF EAST EUROPEAN REGISTRIES ! !

EUROPEAN REGISTRY More information:    phone: (Karolina Zięba) fax: More information:    phone: (Karolina Zięba) fax: